Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma

Benjamin Zhou; Vladislav P Bekerman; Albert S Khouri

doi:10.5005/jp-journals-10078-1386

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma

J Curr Glaucoma Pract. 2022 Sep-Dec;16(3):166-169. doi: 10.5005/jp-journals-10078-1386.

Authors

Benjamin Zhou¹, Vladislav P Bekerman¹, Albert S Khouri¹

Affiliation

¹ Institute of Ophthalmology & Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, United States.

Abstract

Aim: To investigate the long-term efficacy of adjunctive use of latanoprostene bunod (LBN), a new nitric oxide donating prostaglandin medication, in refractory cases of glaucoma at a tertiary care center.

Materials and methods: A review for patients who received add-on LBN was conducted from 1^st January 2018 to 31^st August 2020. A total of 33 patients (53 eyes) met the inclusion criteria of being on ≥3 topical medications, having an intraocular pressure measurement prior to starting LBN, and having adequate follow-up. Baseline demographics, prior treatments, adverse effects, and intraocular pressures measured at baseline, 3, 6, and 12 months were recorded.

Results: Mean baseline intraocular pressure (IOP) [mm Hg ± standard deviation (SD)] was 19.9 ± 6.0. At 3 months, 49 eyes had a mean IOP of 17.3 ± 5.5 (p < 0.01) with an absolute reduction of 2.6 ± 6.6 and a percent reduction of 9 ± 28%. At 6 months, 35 eyes had a mean IOP of 17.2 ± 4.7 (p < 0.01) with an absolute reduction of 3.6 ± 7.4 and a percent reduction of 11 ± 30%. At 12 months, 28 eyes had a mean IOP of 16 ± 4.5 (p < 0.01) with an absolute reduction of 5.8 ± 7.4 and a percent reduction of 19 ± 38%. Over the course of the study, 18 eyes were lost to follow-up. Three eyes had a laser trabeculoplasty, and four eyes required incisional surgery. No eyes discontinued the medication due to adverse effects.

Conclusion: Adjunctive use of LBN in refractory glaucoma showed clinically and statistically significant IOP reductions at 3, 6, and 12-month time points. IOP reduction in patients was stable throughout the course of the study, with the largest decreases seen at the 12-month interval.

Clinical significance: LBN was well tolerated by patients and may be useful as an additive agent in providing long-term intraocular pressure reduction for patients with severe glaucoma on maximal therapy.

How to cite this article: Zhou B, Bekerman VP, Khouri AS. Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma. J Curr Glaucoma Pract 2022;16(3):166-169.

Keywords: Glaucoma; Intraocular pressure; Latanoprostene bunod; Prostaglandin analog.